Full results & analysis
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Terameprocol for Cervical Intraepithelial Neoplasia
NCT00154089Phase 2
Key facts
- Status
- Completed
- Start
- Nov 2004
- Primary completion
- Apr 2006
- Countries
- 1
- Sponsor
- Erimos Pharmaceuticals
- Modality
- Small Molecules
- Drugs
- terameprocol
- Conditions
- cervical intraepithelial neoplasia (CIN)
01
Overview
Phase 2, open-label trial of terameprocol in cervical intraepithelial neoplasia (CIN) (2 arms), sponsored by Erimos Pharmaceuticals. Primary endpoints: Safety and Tolerability and Efficacy. Started Nov 2004; status: completed.
02
Design
2 arms- Study design
- Non-randomizedOpen-label
Terameprocol 45 mg
45 mg/application (1% w/w)
Terameprocol 90 mg
90 mg/application (2% w/w)
03
Endpoints
Primary
Safety and Tolerability
Efficacy
Secondary
Pharmacokinetics
Beyond the preview
Go deeper on NCT00154089.
Full results, competitive context and analysis are in the Gosset platform.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00154089.